At Würzburg University in Germany, scientists have uncovered a paradox tucked inside one of our essential nutrients: vitamin B2, or riboflavin, may be helping cancer cells resist death. The discovery, made by researchers at the Rudolf Virchow Centre and published in Nature Cell Biology, reveals that the very protective pathways our bodies depend on to absorb this crucial vitamin from dairy, eggs, meat, and green vegetables can also shield tumors from a form of programmed destruction called ferroptosis.
This matters because ferroptosis represents one of the body's most powerful natural defenses against cancer. Unlike typical cell death, ferroptosis occurs when iron-driven damage overwhelms a cell's ability to protect itself from oxidative stress—essentially, the cell drowns in its own rust. It's a process the body normally harnesses to eliminate damaged or dangerous cells without triggering inflammation in surrounding tissue. Cancer cells, however, have evolved cunning ways to dodge this fate, strengthening their antioxidant defenses to survive the very stress that should kill them.
The Würzburg team, led by Professor José Pedro Friedmann Angeli, discovered that vitamin B2 metabolism is central to these cancer cell survival strategies. PhD student Vera Skafar and her colleagues found that a protein called FSP1, which helps cells evade unwanted death, depends on vitamin B2 for its protective activity. When the researchers limited vitamin B2 in cancer cell models using genome editing, something striking happened: the cancer cells became dramatically more sensitive to ferroptosis.
This insight opened a new therapeutic direction. If blocking vitamin B2 metabolism in tumors could trigger cell death, could researchers design drugs to do exactly that? The team tested roseoflavin, a naturally occurring compound produced by bacteria with a structure similar to vitamin B2. In laboratory experiments, roseoflavin successfully triggered ferroptosis in cancer cells at low concentrations—proof that the concept works.
"It turned out that roseoflavin triggers ferroptosis in low concentrations," Friedmann Angeli said. "Our experiments show the feasibility of this concept." The findings suggest a pathway forward: developing more effective inhibitors of vitamin B2 metabolism as a new class of cancer therapies.
But the implications reach far beyond oncology. Ferroptosis is emerging as a critical mechanism in neurodegenerative diseases, organ transplant damage, and tissue injury from blocked blood flow. Understanding how vitamin B2 influences ferroptosis could help scientists untangle these complex conditions and potentially unlock new treatments. Friedmann Angeli's research is already expanding in this direction, supported by a nearly two-million-euro ERC Consolidator Grant awarded in May 2024 as part of the DeciFerr project.
The path from laboratory discovery to clinic remains long. The Würzburg team now plans to develop more potent inhibitors and test them in preclinical cancer models. Yet the discovery itself—that an essential nutrient could be retasked as a cancer therapy target—hints at the kind of unexpected turning points that often precede medical breakthroughs. Sometimes the answer to fighting disease lies hidden in plain sight, waiting for the right question to be asked.